{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T23:48:58Z","timestamp":1648511338685},"reference-count":31,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2020,11,28]]},"DOI":"10.1536\/ihj.20-285","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T22:06:30Z","timestamp":1603836390000},"page":"1135-1141","source":"Crossref","is-referenced-by-count":1,"title":["Elevated Serum Levels of Alkaline Phosphatase and the Risk of Low Responsiveness to Clopidogrel"],"prefix":"10.1536","volume":"61","author":[{"given":"Yicong","family":"Ye","sequence":"first","affiliation":[{"name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiliang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Tu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Wallentin L, Becker RC, Budaj A, <i>et al<\/i>. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.","DOI":"10.1056\/NEJMoa0904327"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wiviott SD, Braunwald E, McCabe CH, <i>et al<\/i>. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.","DOI":"10.1056\/NEJMoa0706482"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Roe MT, Armstrong PW, Fox KA, <i>et al<\/i>. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-309.","DOI":"10.1056\/NEJMoa1205512"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. De Luca L, Zeymer U, Claeys MJ, <i>et al<\/i>. Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of 5 contemporary European registries. Eur Heart J Cardiovasc Pharmacother 2020.","DOI":"10.1093\/ehjcvp\/pvaa002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sahl\u00e9n A, Varenhorst C, Lagerqvist B, <i>et al<\/i>. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J 2016; 37: 3335-42.","DOI":"10.1093\/eurheartj\/ehw284"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ahn JH, Ahn Y, Jeong MH, <i>et al<\/i>. Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health. J Cardiol 2020; 75: 478-84.","DOI":"10.1016\/j.jjcc.2019.11.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, <i>et al<\/i>. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-16.","DOI":"10.1016\/j.jacc.2006.11.044"},{"key":"8","unstructured":"8. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-8."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Stone GW, Witzenbichler B, Weisz G, <i>et al<\/i>. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614-23.","DOI":"10.1016\/S0140-6736(13)61170-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Targher G, Byrne CD. Circulating markers of liver function and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2015; 35: 2290-6.","DOI":"10.1161\/ATVBAHA.115.305235"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 2014; 236: 7-17.","DOI":"10.1016\/j.atherosclerosis.2014.06.006"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Park JB, Kang DY, Yang HM, <i>et al<\/i>. Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. Eur Heart J 2013; 34: 920-31.","DOI":"10.1093\/eurheartj\/ehs419"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gurbel PA, Bliden KP, Guyer K, <i>et al<\/i>. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-6.","DOI":"10.1016\/j.jacc.2005.07.041"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301-9.","DOI":"10.1016\/j.lab.2004.01.011"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sambu N, Radhakrishnan A, Dent H, <i>et al<\/i>. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. Heart 2012; 98: 706-11.","DOI":"10.1136\/heartjnl-2011-301164"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tang YD, Wang W, Yang M, <i>et al<\/i>. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE Trial. Circulation 2018; 137: 2231-45.","DOI":"10.1161\/CIRCULATIONAHA.117.030190"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Tonelli M, Curhan G, Pfeffer M, <i>et al<\/i>. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009; 120: 1784-92.","DOI":"10.1161\/CIRCULATIONAHA.109.851873"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Increased serum alkaline phosphatase as a predictor of long-term mortality after stroke. Neurology 2010; 75: 1995-2002.","DOI":"10.1212\/WNL.0b013e3181ff966a"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gopalakrishnan M, Lotfi AS. Stent thrombosis. Semin Thromb Hemost 2018; 44: 46-51.","DOI":"10.1055\/s-0037-1606178"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shantouf R, Kovesdy CP, Kim Y, <i>et al<\/i>. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1106-14.","DOI":"10.2215\/CJN.06091108"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Narisawa S, Harmey D, Yadav MC, O&apos;Neill WC, Hoylaerts MF, Mill\u00e1n JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-10.","DOI":"10.1359\/jbmr.070714"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Park DW, Yun SC, Lee JY, <i>et al<\/i>. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009; 120: 1987-95.","DOI":"10.1161\/CIRCULATIONAHA.109.876763"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Montone RA, Ferrante G, Bac\u00e0 M, Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiol 2010; 6: 167-79.","DOI":"10.2217\/fca.09.159"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hatmi M, Haye B, Gavaret JM, Vargaftig BB, Jacquemin C. Alkaline phosphatase prevents platelet stimulation by thromboxane-mimetics. Br J Pharmacol 1991; 104: 554-8.","DOI":"10.1111\/j.1476-5381.1991.tb12467.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Margolin N, True TA, Saussy DL Jr, Mais DE. Effect of alkaline phosphatase on thromboxane mimetic induced platelet activation. Prostaglandins 1994; 48: 235-46.","DOI":"10.1016\/0090-6980(94)90010-8"},{"key":"26","unstructured":"26. Weitberg AB. The effect of alkaline phosphatase on platelet aggregation. Haematologica (Budap) 1989; 22: 65-8."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Zhou YJ, Zou H, Zheng JN, <i>et al<\/i>. Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. Expert Rev Gastroenterol Hepatol 2017; 11: 269-76.","DOI":"10.1080\/17474124.2017.1283984"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Malehmir M, Pfister D, Gallage S, <i>et al<\/i>. Platelet GPIbalpha is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat Med 2019; 25: 641-55.","DOI":"10.1038\/s41591-019-0379-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gremmel T, Mueller M, Koppensteiner R, Panzer S. Liver function is associated with response to clopidogrel therapy in patients undergoing angioplasty and stenting. Angiology 2016; 67: 835-9.","DOI":"10.1177\/0003319715609011"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Haarhaus M, Brandenburg V, Kalantar-Zadeh K, Stenvinkel P, Magnusson P. Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol 2017; 13: 429-42.","DOI":"10.1038\/nrneph.2017.60"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Haarhaus M, Ray KK, Nicholls SJ, <i>et al<\/i>. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis 2019; 290: 59-65.","DOI":"10.1016\/j.atherosclerosis.2019.09.002"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/6\/61_20-285\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T03:46:09Z","timestamp":1606535169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/6\/61_20-285\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-285","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,28]]}}}